aminoglutethimide has been researched along with Adrenal Cortex Cancer in 17 studies
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Surgery with immediate adjuvant long term mitotane administration was the most effective form of therapy for patients with adrenocortical carcinoma." | 3.69 | Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. ( Kasperlik-Załuska, AA; Makowska, AM; Migdalska, BM; Zgliczyński, S, 1995) |
| "Mitotane is a direct adrenolytic, and is the only drug currently available that has extended survival in patients with this disease." | 2.37 | Treatment of adrenocortical carcinoma: a case report and review of the literature. ( Garnett, WR; May, CA, 1986) |
| "In the therapy of patients with adrenocortical cancer, mitotane can cause an increase in of necrosis and fibrosis, but also in intracellular lipid." | 1.33 | [Effects of drugs on the adrenal cortex and its tumors]. ( Fassnacht, M; Saeger, W, 2006) |
| "Aminoglutethimide was examined only for effects on CYP11A activity and was shown to inhibit pregnenolone formation (20 microM: 61 +/- 4% of control)." | 1.31 | Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. ( Johansson, MK; Lund, BO; Sanderson, JT, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (52.94) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feltus, FA | 1 |
| Cote, S | 1 |
| Simard, J | 1 |
| Gingras, S | 1 |
| Kovacs, WJ | 1 |
| Nicholson, WE | 1 |
| Clark, BJ | 1 |
| Melner, MH | 1 |
| Saeger, W | 1 |
| Fassnacht, M | 3 |
| Plager, JE | 1 |
| Ivković, T | 1 |
| Moore, RN | 1 |
| Penney, DP | 1 |
| Averill, KT | 1 |
| Miller, JW | 1 |
| Crapo, L | 1 |
| Kasperlik-Załuska, AA | 1 |
| Migdalska, BM | 1 |
| Zgliczyński, S | 1 |
| Makowska, AM | 1 |
| Stevens, VL | 1 |
| Xu, T | 1 |
| Lambeth, JD | 1 |
| Beuschlein, F | 2 |
| Vay, S | 1 |
| Mora, P | 1 |
| Allolio, B | 2 |
| Reincke, M | 2 |
| Hahner, S | 1 |
| Klink, A | 1 |
| Johansson, MK | 1 |
| Sanderson, JT | 1 |
| Lund, BO | 1 |
| Kishi, DT | 1 |
| Touitou, Y | 1 |
| Bogdan, A | 1 |
| Auzeby, A | 1 |
| Dommergues, JP | 1 |
| deAsis, DN | 1 |
| Samaan, NA | 1 |
| Scott, RD | 1 |
| Doris, PA | 1 |
| Kilgore, MW | 1 |
| Durham, D | 1 |
| Alberts, D | 1 |
| Stocco, DM | 1 |
| May, CA | 1 |
| Garnett, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer[NCT01255137] | Phase 2 | 13 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome[NCT00569582] | Phase 3 | 50 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse events module. (NCT01255137)
Timeframe: 3/2/11 - 8/2/12
| Intervention | Participants (Number) |
|---|---|
| Adrenal Cortex Neoplasms | 13 |
Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10mm. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameter. Progressive disease (PD) is a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: the appearance of one or more new lesions is also considered progression). Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking s reference the smallest sum diameters while on study. (NCT01255137)
Timeframe: 2 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progression | Stable Disease | |
| Adrenal Cortex Neoplasms | 0 | 0 | 13 | 0 |
Responder is defined as subject with a decrease greater than or equal to 5mm Hg in diastolic blood pressure from baseline to week 24 or last visit. (NCT00569582)
Timeframe: Baseline to Week 24
| Intervention | participants (Number) |
|---|---|
| Mifepristone | 8 |
Responder is defined as subject with a decrease greater than or equal to 25% in area under the curve for glucose on 2-hour oral glucose test from baseline to week 24 or last visit, for Cushing's patients with type-2 diabetes mellitus/impaired glucose tolerance. (NCT00569582)
Timeframe: Baseline to Week 24
| Intervention | participants (Number) |
|---|---|
| Mifepristone | 15 |
4 reviews available for aminoglutethimide and Adrenal Cortex Cancer
| Article | Year |
|---|---|
The medical treatment of Cushing's syndrome.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Aminoglutethimide; Animals; Bromocriptine; Cushing Syndrom | 1993 |
New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Aminoglutethimide; Cell Division; Cholesterol Side-Chain C | 2000 |
Current therapeutic concepts--Cushing's syndrome.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocorticotropic Hormone; Aminoglutethimide; Ci | 1975 |
Treatment of adrenocortical carcinoma: a case report and review of the literature.
Topics: Adrenal Cortex Neoplasms; Adult; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; | 1986 |
13 other studies available for aminoglutethimide and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene.
Topics: Adrenal Cortex Neoplasms; Aminoglutethimide; Dexamethasone; DNA-Binding Proteins; Enzyme Activation; | 2002 |
[Effects of drugs on the adrenal cortex and its tumors].
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Aminoglutethimide; Antineopla | 2006 |
Carcinoma of the adrenal cortex: clinical description, diagnosis, and treatment.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocorticotropi | 1984 |
[Use of aminoglutethimide in a patient with carcinoma of the adrenal cortex].
Topics: Adrenal Cortex Neoplasms; Aminoglutethimide; Carcinoma; Female; Humans; Middle Aged | 1983 |
Fine structural and biochemical effects of aminoglutethimide and o,p'-DDD on rat adrenocortical carcinoma 494 and adrenals.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Aminoglutethimide; Animals; Cholesterol; Corticosterone; M | 1980 |
Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Car | 1995 |
Cholesterol trafficking in steroidogenic cells. Reversible cycloheximide-dependent accumulation of cholesterol in a pre-steroidogenic pool.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adrenal Cortex Neoplasms; Aminoglutethimide; Animals; Choles | 1993 |
Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line.
Topics: Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Analysis of V | 1998 |
Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line.
Topics: Adrenal Cortex Neoplasms; Aminoglutethimide; Carcinoma; Chromatography, High Pressure Liquid; Colfor | 2002 |
Glucocorticoid and mineralocorticoid pathways in two adrenocortical carcinomas: comparison of the effects of o,p'-dichlorodiphenyldichloroethane, aminoglutethimide and 2-p-aminophenyl-2-phenylethylamine in vitro.
Topics: Adrenal Cortex Neoplasms; Adult; Aminoglutethimide; Aniline Compounds; Child; Cortodoxone; Desoxycor | 1979 |
Feminizing adrenocortical carcinoma with Cushing's syndrome and pseudohyperparathyroidism.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adult | 1978 |
Treatment of an adrenal cortical carcinoma with a combination of o,p'-DDD and aminoglutethimide.
Topics: 11-Hydroxycorticosteroids; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenalectomy; Adult; | 1975 |
An endogenous digitalis-factor derived from the adrenal gland: studies of adrenocortical tumor cells.
Topics: Adrenal Cortex Neoplasms; Aminoglutethimide; Animals; Blood Proteins; Cardenolides; Cell Line; Digox | 1989 |